NCT07652242
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07652242
Title First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC ) (VITAL-TNBC)
Acronym VITAL-TNBC
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Immunomic Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.